Chronic kidney disease and cardiovascular risk

Journal of the American Society of Hypertension

Volumn 1, Issue 3, 2007, Pages 178-184

  Yerram, Preethi ^a   Karuparthi, Poorna R ^a   Hesemann, Laura ^a   Horst, Jennifer ^a   Whaley Connell, Adam ^a  

^a University of Missouri   (United States)

Author keywords

cardiometabolic syndrome; microalbuminuria; oxidative stress; proteinuria; Uremia related risk factors

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; ERYTHROPOIETIN; HOMOCYSTEINE; PHOSPHORUS; RENIN INHIBITOR;

AGE; ANEMIA; ARTERY COMPLIANCE; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; COMORBIDITY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PUBLIC HEALTH PROBLEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; UREMIA;

EID: 34249101957     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2007.01.010     Document Type: Review

References (55)

1. Fried L., Kronmal R., Newman A., et al., Cardiovascular Health Study Collaborative Research Group Risk Factors for 5-Year Mortality in Older Adults: the Cardiovascular Health Study. JAMA 279 (1998) 585-592
2. Mann J., Gerstein H., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
3. Schillaci G., Reboldi G., and Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 161 (2001) 886-891
4. Shulman N., Ford C., Hall W., et al., The Hypertension Detection and Follow-up Program Cooperative Group Hypertension. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 13 (1989) I80-I93
5. Collins A.J., Li S., Gilbertson D.T., Liu J., Chen S.C., and Herzog C.A. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 64 Suppl 87 (2003) S24-S31
6. Drey N., Roderick P., Mullee M., and Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 42 (2003) 677-684
7. Levey A.S., Beto J.A., Coronado B.E., et al., National Kidney Foundation Task Force on Cardiovascular Disease. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis 32 (1998) 853-906
8. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 5 Suppl 3 (1998) S112-S119
9. th ed. (2005), McGraw-Hill, New York, New York 1653-1663
10. Sarnak M., Levey A., Schoolwerth A., and Coresh J. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2159
11. Berl T., and Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 1 (2006) 8-18
12. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. [see comment]. N Engl J Med 351 (2004) 1296-1305
13. Sarnak M.J., and Levey A.S. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35 4 Suppl 1 (2000) S117-S131
14. Block G., and Port F.K. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial 16 (2003) 140-147
15. Ford E., Giles W., and Dietz W. Prevalence of the metabolic syndrome among US adults findings from The Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
16. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140 (2004) 167-174 [see comment]
17. Muntner P., He J., Chen J., Fonseca V., and Whelton P. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14 (2004) 6686-6695
18. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. [see comment]. J Am Soc Nephrol 16 (2005) 2134-2140
19. Kahn R., Buse J., Ferrannini E., Stern M., and Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal. Diabetologia 48 (2005) 1684-1699
20. Shlipak M., Fried L., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
21. Foley R., Parfrey P., Harnett J., Kent G., Murray D., and Barre P. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996) 53-61
22. Blacher J., Safar M., Guerin A., Pannier B., Marchais S., and London G. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63 (2003) 1852-1860
23. Rostand S., and Dreke T. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56 (1999) 383-392
24. Jono S., McKee M.D., Murry C., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 (2000) e10-e17.
25. Guerin A., London G., Marchais S., and Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 (2000) 1014-1021
26. Stevens L.A., and Levin A. Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. Curr Opin Nephrol Hypertens 12 (2003) 133-138
27. Portoles J., Torralbo A., Martin P., Rodrigo J., and Herrero J. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29 (1997) 541-548
28. Besarab A., Bolton W., Browne J., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
29. Foley R., Parfrey P., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 (2000) 1325-1335
30. Malinow M., Sexton G., Averbuch M., Grossman M., Wilson D., and Upson B. Homocyst(e)inemia in daily practice: levels in coronary heart disease. Coron Artery Dis 1 (1990) 215-220
31. Boston A., and Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcome. Kidney Int 52 (1997) 10-20
32. Arici M., and Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. Kidney Int 59 (2001) 407-414
33. Ridker P., Cushman M., Stampher M., Tracy R.P., and Hennekens C. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 976-979
34. Varagunam M., Finney H., Trevitt R., et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis 43 (2004) 502-507
35. Noh H., Lee S., Kang S., et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 18 (1998) 387-394
36. Defilipp C., Wasserman S., Rosanio S., et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290 (2003) 353-359
37. Knight E., Rimm E., Pai J., et al. Kidney dysfunction, inflammation, and coronary events: a Prospective Study. J Am Soc Nephrol 15 (2004) 1897-1903
38. Galli F., Canestrari F., and Buoncristani U. Biological effects of oxidant stress in haemodialysis: the possible roles of vitamin E. Blood Purif 17 (1999) 79-94
39. Cockcroft D., and Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
40. Levey A., Bosch J., Lewis J., Greene T., Rogers N., Roth D., and Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
41. Levey A., Greene T., Kusek J., and Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. [abstract]. J Am Soc Nephrol 11 (2000) 155A
42. Keane W., and Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004-1010
43. Remuzzi G., and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339 (1998) 1448-1456
44. Cohn J., Quyyumi A., Hollenberg N., and Jamerson K. Surrogate markers for cardiovascular disease: functional markers. Circulation 109 25 Suppl 1 (2004) 31-46
45. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39 Suppl 1 (2002) S1-S266
46. American Diabetes Association. Clinical practice recommendations. Diabetes Care 24 (2001) S1-S133
47. Warram J., Gearin G., Laffel L., and Krolewski A. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7 (1996) 930-937
48. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., Schroll M., and Jensen J. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19 (1999) 1992-1997
49. ADA. ADA position statement: nephropathy in diabetes. Diabetes Care 27 Suppl 1 (2004) S79-S83
50. Agodoa L.Y., Appel L., Bakris G.L., and African-American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
51. Brenner B.M., Cooper M.E., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
52. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
53. Weir M.R. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 18 (2005) S100-S105
54. Jamerson K.A. Preventing chronic kidney disease in special populations. Am J Hypertens 18 (2005) S106-S111
55. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA 289 (2003) 2560-2572